Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

245

P561 Clinical Characteristics and Survival According to the Presence of Velcro Crackles in the European Multipartner IPF Registry (EMPIRE)/ D. Lang, Linz, Austria

P545 Oscillometry and Spirometry in Fibrotic Versus Non-fibrotic Interstitial Lung Disease/ F. Gabrysz-Forget, Montreal, Canada P546 Utility of Using Ultrasound and Spirometry in Predicting Transdiaphragmatic Pressure (Pdi) in Patients With Moderate to Severe IIP/ K.R. Thapa, Kathmandu, Nepal P547 FVC/DLCO Ratio in Patients With Fibrotic HP Versus IPF/ T.S. Vongvivitpatana, San Antonio, TX P548 Bilateral Bronchoalveolar Lavage in the Workup of Interstitial Lung Disease/ G. George, Philadelphia, PA P549 Usefulness of Performing Two Bronchoalveolar Lavages in Patients With Interstitial Lung Diseases/ S.A.M. Alqahtani, Kingston, Canada P550 Identifying Problems in the Morphological Evaluation of Bronchoalveolar Lavage/ Y. Waseda, Eiheiji, Japan P551 Increased Bronchoalveolar Lavage (BAL) Chitin Levels in Patients With Idiopathic Pulmonary Fibrosis (IPF) Are Associated With Decreased Diffusion Capacity/ F. Mclafferty, San Francisco, CA P552 The Impact of Diagnostic Guidelines on Clinician Diagnosis of Hypersensitivity Pneumonitis/ J. Gu, Durham, NC P553 Computed Tomography Features Influencing Guideline-defined Radiologic Patterns In Interstitial Lung Disease/ D. Marinescu, Vancouver, Canada P554 Radiologic Patterns and Leading Clinical Diagnoses in Unclassifiable Interstitial Lung Disease/ L. Minuk, Toronto, Canada P555 The Impact of Genomic Classifier in Patients With Undiagnosed Interstitial Lung Disease/ D.E. Espinoza Barrera, New Orleans, LA P556 Predicting Interstitial Pulmonary Fibrosis Using a Machine Learning Classifier in Cases Without Definite or Probable Usual Interstitial Pneumonia Pattern on Computed Tomography/ Y. Ahmad, Cincinnati, OH P557 A Machine Learning System to Predict Diagnosis of Idiopathic Pulmonary Fibrosis Non-Invasively in Challenging Cases/ Y. Ahmad, Cincinnati, OH P558 Association Between Histological Classification and Prognosis Using AI Classification for Lung Pathology of Diffuse Parenchymal Lung Disease/ T. Niwa, Yokohama, Japan P559 Gene Signature of Acute Interstitial Pneumonia/ H.J. Yeo, Yangsan, Korea, Republic of P560 Rural Versus Urban Disparities in Access to Care and Treatment of Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry/ R. Boente, Indianapolis, IN

CLINICAL THEMATIC POSTER SESSION

C40

CLINICAL TRIALS AND NOVEL INTERVENTIONS IN COPD

9:00 a.m. - 4:15 p.m.

Walter E. Washington Convention Center Area B, Hall C (Lower Level)

Viewing: Posters will be on display for entire session

11:30-1:15

Discussion: 11:30-12:15 authors will be present for individual discussion 12:15-1:15 authors will be present for discussionwith assigned facilitators. P166 Treatment With Ensifentrine, a Dual PDE3 and PDE4 Inhibitor, Significantly Reduced Exacerbation Rate and Risk in Subjects With COPD: Sub-group Results From the Phase 3 Trial, Enhance-2/ A. Anzueto, San Antonio, TX P167 Ensifentrine, a Dual Inhibitor of PDE3 and PDE4, Reduces the Risk of Exacerbation Regardless of Background Medication Use: A Sub-group Analysis of ENHANCE-2, a Phase 3 Trial/ G.T. Ferguson, Fountain, MI P168 Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, in Moderate and Severe COPD: Symptoms, Quality of Life and Health Status From the Phase 3 Trial Enhance-2/ T. Rheault, Cary, NC P169 Oral Treatment With Quercetin Reduces Markers of Inflammation in COPD Patients/ S. Patel, Philadelphia, PA P170 Safety, Efficacy, and Portrait of SARS-CoV-2 Vaccination in Chronic Obstructive Pulmonary Disease (COPD) Patients: A Cohort Study/ É. Pelletier, Québec, Canada P171 Safety Results From Dual PDE3/4 Inhibitor Ensifentrine: Gastrointestinal and Cardiovascular Safety From a 24-week Phase 3 Trial, Enhance-2/ T.M. Siler, Saint Charles, MO P172 Twice-daily, Nebulized Ensifentrine Significantly Improves Lung Function: Sub-group Analysis in the Phase 3 Trial ENHANCE-1/ T.M. Siler, Saint Charles, MO P173 Ensifentrine, a Novel Dual Phosphodiesterase (PDE) 3 and 4 Inhibitor, Improves Lung Function, Symptoms, Quality of Life and Reduces Exacerbation Rate and Risk in Patients With COPD: Results From Replicate Phase 3 Trials/ F.C. Sciurba, Pittsburgh, PA

ATS 2023 • Washington, DC